Pular para o conteúdo principal
Ranking Invest

GMAB - Genmab A/S

Segmento: HealthcareGenmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company's also develops products, which is in Phase 2 comprise Teclistamab for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Análise Ranking Invest

Valor de Mercado
$ 27.48 Bi
IVR
0.86Índice proprietário de comparação relativa: 0,86.
IVR2
0.67Leitura proprietária complementar: 67%.
MLL
0.67Leitura proprietária complementar: 67%.
Último Balanço Atualizado: 1T2025

O Ranking Invest utiliza metodologia proprietária baseada em dados financeiros públicos; fórmulas e valores intermediários são confidenciais.

Dados da Empresa

Patrimônio Líquido

$ 5.30 Bi

Dívida Líquida

-$ 1.48 Bi

L4T

$ 6.71 Bi

MM4T

28.14%

Indicadores Básicos

ROE

126.77%

Índices de Previsibilidade

Receita Líquida

D0.12

Lucro

D0.55

Margem

C0.50

Índices de Tendência

Receita Líquida

B10.31

Lucro

C3.69

Margem

D-1.02

Índices de Endividamento

DIV/PAT

-0.28

DIV/L4T

-0.22

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.